Ventilation Devices MarketSize, Share & Industry Analysis, 2026-2034By TypeBy ApplicationBy Patient TypeBy MobilityBy Component

Ventilation devices are medical equipment used to support or fully replace a patient's own breathing when lung function is impaired, ranging from invasive units connected through an endotracheal or tracheostomy tube to non-invasive units delivering pressurized air through a mask or nasal interface. Buyers include hospital critical-care and surgical recovery units, home care providers managing chronically ventilator-dependent patients, and ambulance and outpatient clinic operators that need portable units for transport and short-term respiratory support.

Between 2025 and 2034 the global ventilation devices market moves from USD 4.5 billion to USD 8.63 billion, compounding at 7.5% a year. Fifteen years are covered in all, taking in USD 3.28 billion in 2020, USD 4.23 billion in 2024, USD 4.84 billion in 2026 and USD 6.46 billion in 2030.

On the type axis, growth rates run from 6.43% for Invasive Ventilation Devices up to 8.88% for Non-invasive Ventilation Devices. Invasive Ventilation Devices carries the volume: USD 2.66 billion and 59.11% of revenue in 2025, USD 4.66 billion and 54% in 2034. Non-invasive Ventilation Devices take share over the period; Invasive Ventilation Devices give it up while still growing in absolute terms.

By application, Hospital accounts for 68% of 2025 revenue at USD 3.06 billion, reaching USD 5.35 billion and 62% by 2034. Home Care grows faster at 10.21% against 6.4%, moving from 24% of revenue to 30% by 2034. This axis divides the same revenue as the type split instead of adding to it, so the two are read together and never summed.

North America is the largest region at 38% of 2025 revenue, worth USD 1.71 billion and reaching USD 2.93 billion by 2034. Europe follows at 26%, moving from USD 1.17 billion to USD 2.07 billion, and Middle East and Africa is the smallest at 6%. Share shifts toward Asia Pacific, Latin America and Middle East and Africa over the forecast period, so the regional split repays a close reading.

Coverage extends to five regions, two type lines and five segmentation axes over the full fifteen years. The 2025 total itself is a triangulation of published figures and category proxies, short of a directly sourced total, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.

• Revenue grows from USD 4.5 billion in 2025 to USD 8.63 billion in 2034, a compound annual rate of 7.5%, having reached USD 4.23 billion in 2024 from USD 3.28 billion in 2020.
• The largest line by type is Invasive Ventilation Devices, worth USD 2.66 billion and 59.11% of revenue in 2025, rising to USD 4.66 billion and 54% by 2034.
• Non-invasive Ventilation Devices is the fastest-growing line at 8.88%, lifting its share from 40.89% in 2025 to 46% in 2034 and its revenue from USD 1.84 billion to USD 3.97 billion.
• The bull case puts 2034 revenue at USD 9.67 billion and the bear case at USD 7.77 billion, either side of the USD 8.63 billion base case, each with its own stated assumption in the full report.
• 38% of 2025 revenue is generated in North America, worth USD 1.71 billion and rising to USD 2.93 billion by 2034; Middle East and Africa is smallest at 6%.
• 84.8% of North America's base-year revenue comes from the United States alone: USD 1.45 billion in 2025, rising to USD 2.49 billion by 2034, which is why it is that region's worked example.
• The study covers 2020 through 2034 with 2025 as the base year, reporting five regions and five segmentation axes separately, with revenue, share and a growth rate for every line in each year.

Three movements define the forecast period in the global ventilation devices market: how the type mix changes, where regional weight shifts, and the rate at which the total compounds.

All three are changes in mix, not in direction: nothing contracts, and the movement is in which lines and regions absorb the new revenue.

The type mix tilts toward Non-invasive Ventilation Devices. Non-invasive Ventilation Devices grows at 8.88% across 2026-2034 against 6.43% for Invasive Ventilation Devices, the widest spread on the type axis. By 2034 the two sit at 46% and 54% of revenue, against 40.89% and 59.11% in 2025. In absolute terms Non-invasive Ventilation Devices rises from USD 1.84 billion to USD 3.97 billion, while Invasive Ventilation Devices rises from USD 2.66 billion to USD 4.66 billion. Both grow; the gap is wide enough to reshape the mix inside a single forecast window.

Regional weight shifts toward Asia Pacific, Latin America and Middle East and Africa. Asia Pacific moves from 24% of revenue in 2025 to 30.01% in 2034, worth USD 1.08 billion rising to USD 2.59 billion; Latin America moves from 6% of revenue in 2025 to 6.03% in 2034, worth USD 0.27 billion rising to USD 0.52 billion; Middle East and Africa moves from 6% of revenue in 2025 to 6.03% in 2034, worth USD 0.27 billion rising to USD 0.52 billion. The remaining regions grow in absolute terms while giving up share: North America at 38% moving to 33.95%, Europe at 26% moving to 23.99%. That makes the regional split worth reading directly instead of scaling from the global rate: the same market rate produces different outcomes depending on where a supplier's revenue sits.

The series never breaks trajectory. Fifteen years of revenue run USD 3.28 billion in 2020, USD 4.23 billion in 2024, USD 4.5 billion in 2025, USD 4.84 billion in 2026, USD 6.46 billion in 2030 and USD 8.63 billion in 2034. There is no discontinuity to time, and 7.5% forecast growth against 6.53% historical means the trend continues and does not turn. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the type and regional axes, not by the headline rate.

Non-invasive Ventilation Devices adds the most incremental growth

Separate the 7.5% into its parts and three show up: an already-large base compounding, the type mix moving toward its faster lines, and regional growth landing unevenly.

The bear case and what drives it

What the bull case turns on

Concentration on the type axis

USD 1.71 billion of 2025 revenue is generated in North America, 38% of the global ventilation devices market rising to USD 2.93 billion in 2034. By revenue it sits first across the study, and the ranking does not change between 2025 and 2034.

By 2034 the share stands at 33.95%, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.

The type mix reported at global level applies here, with Invasive Ventilation Devices the largest line at 59.11% of 2025 revenue and Non-invasive Ventilation Devices the fastest-growing at 8.88%. Per-axis and per-country detail for North America sits in the full report.

The United States is the largest market within North America, generating USD 1.45 billion in 2025 and projected to reach USD 2.49 billion by 2034. Because it is 84.8% of the region in the base year, North America's totals move with this one country instead of a spread of them. Regional revenue of USD 1.71 billion in 2025 and USD 2.93 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

The type pattern in the United States is the global one: 59.11% of 2025 revenue in Invasive Ventilation Devices, 54% by 2034, against 8.88% growth in Non-invasive Ventilation Devices taking it from 40.89% to 46%. With 84.8% of North America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Per-type revenue for the United States appears on its own in the full report.

In the United States, ventilation devices fall under the Food and Drug Administration's medical device framework, administered through the Center for Devices and Radiological Health. Most ventilators and related respiratory support equipment are classified as moderate-risk devices, requiring premarket notification through the FDA's clearance pathway before a manufacturer can market the product domestically. Devices intended for life-sustaining or life-supporting use may face closer scrutiny given the risk to patients if the equipment fails. Manufacturers must also comply with the agency's quality system requirements covering design controls, production, and post-market surveillance, plus labeling rules that state intended use, warnings, and operating instructions clearly enough for clinical staff to follow without ambiguity.

Allied Healthcare Products, Philips Healthcare, ResMed, Smiths, Teleflex, Hamilton Medical, GE Healthcare, Medtronic, Becton, Dickinson, Getinge Group and Dragerwerk are the suppliers covered in the United States. The commercially relevant division is 59.11% of 2025 revenue in Invasive Ventilation Devices, where the volume is, against 8.88% growth in Non-invasive Ventilation Devices, where share moves. Country-level shares and positioning per company sit in the full report.

Within North America, Canada accounts for 15.2% of regional revenue and 5.78% of the global total, worth USD 0.26 billion in 2025 and USD 0.44 billion by 2034.

In Europe, 26% of global revenue puts 2025 at USD 1.17 billion with USD 2.07 billion projected for 2034. By revenue it sits second across the study, and the ranking does not change between 2025 and 2034.

Share settles at 23.99% in 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

Within the region the type split tracks the global one; 59.11% of 2025 revenue in Invasive Ventilation Devices, fastest growth of 8.88% in Non-invasive Ventilation Devices. The full report breaks Europe out along every axis and by country.

28.21% of Europe's base-year revenue comes from Germany; USD 0.33 billion, rising to USD 0.58 billion by 2034. Its 28.21% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. Against regional totals of USD 1.17 billion in 2025 and USD 2.07 billion in 2034, it is the country the full report breaks out in detail.

Demand in Germany follows the type mix reported at global level: Invasive Ventilation Devices is the largest line at 59.11% of 2025 revenue, moving to 54% by 2034, while Non-invasive Ventilation Devices grows fastest at 8.88% and takes its share from 40.89% to 46%. Its 28.21% weight in Europe means those movements carry straight into the regional totals. Revenue by type for Germany is reported separately in the full report.

Germany applies the European Union's Medical Device Regulation to ventilation devices, meaning a manufacturer must demonstrate conformity through a Notified Body before affixing the CE mark that allows the product to circulate across the bloc. Ventilators and respiratory support devices generally sit in a higher risk class given their role in sustaining breathing, so conformity assessment tends to involve closer review of clinical evidence and quality management systems than lower-risk equipment faces. The Federal Institute for Drugs and Medical Devices oversees market surveillance domestically and coordinates with the broader EU vigilance system for reporting adverse incidents. Labelling must be presented in German and follow the harmonised standards that apply to essential safety and performance requirements.

Competition in Germany runs between the suppliers this study tracks: Allied Healthcare Products, Philips Healthcare, ResMed, Smiths, Teleflex, Hamilton Medical, GE Healthcare, Medtronic, Becton, Dickinson, Getinge Group and Dragerwerk. Volume sits in Invasive Ventilation Devices at 59.11% of 2025 revenue; movement sits in Non-invasive Ventilation Devices at 8.88% growth. The commercial size of that position is USD 1.17 billion in 2025 and USD 2.07 billion by 2034, 26% of the global total in the base year.

Within Europe, the United Kingdom accounts for 22.22% of regional revenue and 5.78% of the global total, worth USD 0.26 billion in 2025 and USD 0.46 billion by 2034.

4.67% of global revenue is generated in France; USD 0.21 billion in 2025, reaching USD 0.37 billion in 2034, and 17.95% of Europe.

24% of the global ventilation devices market sits in Asia Pacific in 2025, worth USD 1.08 billion and reaches USD 2.59 billion by 2034. By revenue it sits third across the study, and the ranking does not change between 2025 and 2034.

By 2034 the share has moved up to 30.01%, on growth above the market's own 7.5%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

Segment composition follows the global pattern: Invasive Ventilation Devices largest at 59.11% of 2025 revenue, Non-invasive Ventilation Devices fastest at 8.88%. Asia Pacific is reported axis by axis and country by country in the full study.

The largest single market in Asia Pacific is China, at USD 0.43 billion in 2025 and USD 1.04 billion in 2034. Its 39.81% of base-year regional revenue leads the region, though enough sits elsewhere that Asia Pacific is not a proxy for it. Against regional totals of USD 1.08 billion in 2025 and USD 2.59 billion in 2034, it is the country the full report breaks out in detail.

The type pattern in China is the global one: 59.11% of 2025 revenue in Invasive Ventilation Devices, 54% by 2034, against 8.88% growth in Non-invasive Ventilation Devices taking it from 40.89% to 46%. Since 39.81% of Asia Pacific's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. The full report reports China by type separately.

China regulates ventilation devices through the National Medical Products Administration, which classifies medical devices by risk and places ventilators in its higher categories because of their role in supporting a patient's breathing. Bringing such a device to market requires registration at the national level, since higher-risk classification keeps this category out of provincial regulators' hands, supported by clinical evaluation data and evidence that the product meets applicable national standards for electrical safety and performance. Manufacturing sites are also subject to quality system inspection under the country's medical device production rules. Labelling and instructions for use must appear in Chinese and disclose the device's intended purpose, contraindications, and handling precautions clearly enough for hospital staff to operate the equipment safely.

Competition in China runs between the suppliers this study tracks: Allied Healthcare Products, Philips Healthcare, ResMed, Smiths, Teleflex, Hamilton Medical, GE Healthcare, Medtronic, Becton, Dickinson, Getinge Group and Dragerwerk. Invasive Ventilation Devices, at 59.11% of 2025 revenue, is where the volume sits, and Non-invasive Ventilation Devices, growing at 8.88%, is where position changes hands over the forecast period. Weighting toward Asia Pacific means competing for 24% of 2025 global revenue, a base of USD 1.08 billion moving to USD 2.59 billion across the forecast period.

Within Asia Pacific, Japan accounts for 22.22% of regional revenue and 5.33% of the global total, worth USD 0.24 billion in 2025 and USD 0.57 billion by 2034.

Within Asia Pacific, India accounts for 14.81% of regional revenue and 3.56% of the global total, worth USD 0.16 billion in 2025 and USD 0.39 billion by 2034.

In Latin America, 6% of global revenue puts 2025 at USD 0.27 billion on the way to USD 0.52 billion by 2034. It is a marginal region on this axis, fourth by revenue throughout the period.

Its share rises to 6.03% over the forecast period, at a pace above the 7.5% global rate, so this region warrants separate treatment and should not be scaled off the total.

Invasive Ventilation Devices leads here as it does globally, at 59.11% of 2025 revenue, and Non-invasive Ventilation Devices again grows fastest at 8.88%. Per-axis and per-country detail for Latin America sits in the full report.

51.85% of Latin America's base-year revenue comes from Brazil; USD 0.14 billion, rising to USD 0.26 billion by 2034. It accounts for 51.85% of regional revenue in the base year, the largest single share without dominating the region outright. Set against USD 0.27 billion and USD 0.52 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

Brazil buys along the same lines as the market globally; Invasive Ventilation Devices first at 59.11% of 2025 revenue and 54% in 2034, Non-invasive Ventilation Devices fastest at 8.88% on a share moving from 40.89% to 46%. Because the country carries 51.85% of Latin America, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Brazil carries its own type breakdown in the full report.

In Brazil, ventilation devices are regulated by ANVISA, the national health surveillance agency responsible for authorising medical devices before they reach the market. Ventilators and related respiratory support equipment are treated as higher-risk products given their function in sustaining a patient's breathing, so a manufacturer must obtain full registration, since the simpler notification route reserved for lower-risk items does not extend to this category, supported by technical and clinical documentation. Good manufacturing practice certification of the production site forms part of that process, alongside conformity with recognised national and international standards covering safety and performance. Labelling must appear in Portuguese and set out the device's intended use, operating limits, and warnings for the clinicians who rely on it.

In Brazil the field is Allied Healthcare Products, Philips Healthcare, ResMed, Smiths, Teleflex, Hamilton Medical, GE Healthcare, Medtronic, Becton, Dickinson, Getinge Group and Dragerwerk. The commercially relevant division is 59.11% of 2025 revenue in Invasive Ventilation Devices, where the volume is, against 8.88% growth in Non-invasive Ventilation Devices, where share moves. That makes Latin America a 6% share of 2025 global revenue, USD 0.27 billion rising to USD 0.52 billion, for any supplier deciding where to concentrate.

Within Latin America, Mexico accounts for 29.63% of regional revenue and 1.78% of the global total, worth USD 0.08 billion in 2025 and USD 0.16 billion by 2034.

In Middle East and Africa, 6% of global revenue puts 2025 at USD 0.27 billion on the way to USD 0.52 billion by 2034. It is a marginal region on this axis, fifth by revenue throughout the period.

6.03% of global revenue sits here by 2034, up from the 2025 level, at a pace above the 7.5% global rate, so this region warrants separate treatment and should not be scaled off the total.

Segment composition follows the global pattern: Invasive Ventilation Devices largest at 59.11% of 2025 revenue, Non-invasive Ventilation Devices fastest at 8.88%. Per-axis and per-country detail for Middle East and Africa sits in the full report.

USD 0.09 billion of Middle East and Africa's 2025 revenue is generated in Saudi Arabia, the region's largest market, reaching USD 0.18 billion by 2034. Its 33.33% of base-year regional revenue leads the region, though enough sits elsewhere that Middle East and Africa is not a proxy for it. Against regional totals of USD 0.27 billion in 2025 and USD 0.52 billion in 2034, it is the country the full report breaks out in detail.

Composition here matches the global split: the largest line is Invasive Ventilation Devices at 59.11% of 2025 revenue, easing to 54% by 2034, and the fastest is Non-invasive Ventilation Devices at 8.88%, from 40.89% to 46%. Since 33.33% of Middle East and Africa's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Revenue by type for Saudi Arabia is reported separately in the full report.

Saudi Arabia regulates ventilation devices through the Saudi Food and Drug Authority, whose medical device sector oversees classification, registration, and post-market monitoring of equipment sold within the kingdom. A manufacturer or its authorised local representative must list the device on the authority's registration system, providing evidence of conformity with recognised international standards and, where the device already holds approval from a reference regulator elsewhere, documentation of that prior clearance. Given their role in supporting breathing, ventilators sit among the higher-risk categories the authority reviews more closely before granting market authorisation. Labelling must appear in Arabic alongside English and state intended use, storage conditions, and safety warnings for clinical users.

In Saudi Arabia the field is Allied Healthcare Products, Philips Healthcare, ResMed, Smiths, Teleflex, Hamilton Medical, GE Healthcare, Medtronic, Becton, Dickinson, Getinge Group and Dragerwerk. Two different problems sit on the same axis: holding Invasive Ventilation Devices at 59.11% of 2025 revenue, and taking Non-invasive Ventilation Devices while it grows at 8.88%. A supplier weighted toward Middle East and Africa is competing over a base of USD 0.27 billion in 2025 reaching USD 0.52 billion by 2034, 6% of global revenue at the start of that period.

1.56% of global revenue is generated in South Africa; USD 0.07 billion in 2025, reaching USD 0.13 billion in 2034, and 25.93% of Middle East and Africa.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Type, Application, Patient Type, Mobility, Component, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.